Quanterix Corp QTRX
We are a life sciences company transforming healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics using our ultra-sensitive translational research and spatial biology instruments, consumables, and services. We continue to invest in pushing a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention. Our combined platforms have achieved significant commercial adoption with an installed base of over 2,500 instruments and scientific validation with citations in more than 6,200 scientific publications in areas of high unmet medical need and research interest such as neurology, oncology, immunology, and inflammation.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $138.9M | $137.4M | $122.4M | $105.5M | $110.6M | $86.4M | $56.7M | $37.6M | $22.9M | $17.6M |
| Cost of revenue | $73.9M | $54.3M | $48.1M | $60.2M | $45.8M | $38.2M | $29.9M | $19.7M | $12.9M | $9.8M |
| Gross profit | $65.0M | $83.1M | $74.2M | $45.4M | $64.8M | $48.2M | $26.8M | $17.9M | $10.0M | $7.7M |
| R&D | $35.9M | $31.1M | $26.1M | $26.8M | $28.4M | $20.2M | $16.2M | $15.8M | $16.3M | $17.0M |
| SG&A | $138.0M | $101.6M | $89.1M | $91.9M | $92.9M | $59.6M | $52.2M | $33.7M | $19.7M | $12.5M |
| Total operating expenses | $190.5M | $135.7M | $120.2M | $149.6M | $121.3M | $79.8M | $68.4M | $49.5M | $36.0M | $29.5M |
| Operating income | -$125.5M | -$52.6M | -$46.0M | -$104.3M | -$56.5M | -$31.6M | -$41.6M | -$31.6M | -$26.0M | -$21.7M |
| Interest expense | $8.6M | $14.7M | $15.8M | $5.1M | $403.0K | $273.0K | $627.0K | $46.0K | $951.0K | $1.3M |
| Pre-tax income | -$112.3M | -$38.1M | -$27.6M | -$99.4M | -$55.6M | -$31.9M | -$41.0M | -$31.5M | -$27.0M | -$23.2M |
| Income tax | $5.1M | $434.0K | $719.0K | $164.0K | $36.0K | $376.0K | $187.0K | $25.0K | $0 | — |
| Net income | -$107.2M | -$38.5M | -$28.4M | -$99.6M | -$55.5M | -$31.5M | -$40.8M | -$31.5M | -$27.0M | -$23.2M |
| EPS, basic | -2.51 | -1.00 | -0.75 | -2.69 | -1.54 | -1.07 | -1.63 | — | — | — |
| EPS, diluted | -2.51 | -1.00 | -0.75 | -2.69 | -1.54 | -1.07 | -1.63 | — | — | — |
| Shares, diluted (wtd. avg.) | $42.6M | $38.4M | $37.6M | $37.0M | $36.0M | $29.6M | $25.1M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $29.8M | $56.7M | $177.0M | $341.3M | $399.3M | $182.6M | $110.2M | $45.4M | $79.7M | $29.7M |
| Short-term investments | $88.4M | $232.4M | $146.9M | $0 | — | — | — | — | — | — |
| Receivables | $30.0M | $32.1M | $25.4M | $19.7M | $22.6M | $17.2M | $10.9M | $6.8M | $5.6M | — |
| Inventory | $54.8M | $32.8M | $26.1M | $22.7M | $24.4M | $14.9M | $10.5M | $5.9M | $3.6M | — |
| Total current assets | $212.3M | $363.6M | $382.1M | $413.9M | $435.5M | $219.6M | $132.7M | $59.5M | $89.3M | — |
| Property, plant and equipment | $23.7M | $17.1M | $17.9M | $22.0M | $19.6M | $13.9M | $12.0M | $2.9M | $1.9M | — |
| Goodwill | $26.4M | $0 | $0 | $8.7M | $9.3M | $10.5M | $9.4M | $1.3M | — | — |
| Other intangibles | $131.8M | $4.0M | $6.0M | $8.5M | $9.7M | $13.7M | $14.3M | $2.3M | — | — |
| Total assets | $418.8M | $406.5M | $428.6M | $488.7M | $506.7M | $271.0M | $170.0M | $67.6M | $91.8M | — |
| Accounts payable | $13.6M | $7.0M | $5.0M | $5.9M | $4.2M | $6.8M | $5.8M | $5.1M | $3.6M | — |
| Short-term debt | — | — | — | — | — | $7.7M | $75.0K | — | $5.0M | — |
| Total current liabilities | $74.8M | $42.0M | $39.0M | $36.7M | $31.8M | $39.8M | $19.8M | $18.1M | $19.7M | — |
| Long-term debt | — | — | — | — | — | $7.7M | $7.6M | $7.6M | $4.3M | — |
| Total liabilities | $123.0M | $76.5M | $78.6M | $83.2M | $78.2M | $64.9M | $41.3M | $26.5M | $25.9M | — |
| Retained earnings | -$577.2M | -$470.1M | -$431.6M | -$348.4M | -$321.5M | -$247.8M | -$216.2M | -$175.9M | -$144.4M | — |
| Total equity | $295.7M | $330.0M | $350.0M | $357.9M | $442.8M | $205.8M | $128.7M | $41.1M | $65.9M | -$115.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77.2M | -$35.2M | -$18.8M | -$48.6M | -$47.6M | -$23.4M | -$26.2M | -$28.7M | -$22.1M | -$17.7M |
| Depreciation and amortisation | $15.8M | $6.5M | $6.3M | $5.4M | $4.9M | $4.3M | $3.0M | $1.4M | $482.0K | $444.0K |
| Stock-based compensation | $20.7M | $20.0M | $16.8M | $15.4M | $16.0M | $10.1M | $6.4M | $4.9M | $2.2M | $928.0K |
| Capital expenditure | $2.6M | $3.4M | $3.8M | $11.6M | $13.7M | $3.9M | $10.8M | $1.5M | $1.1M | $526.0K |
| Investing cash flow | $50.2M | -$82.3M | -$148.5M | -$11.1M | -$6.4M | -$626.0K | -$25.4M | -$5.5M | -$1.1M | -$826.0K |
| Financing cash flow | -$708.0K | $456.0K | $2.7M | $2.3M | $270.8M | $96.2M | $116.2M | -$78.0K | $73.2M | $45.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-048166.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |